Company / Cost of Revenue
Perspective Therapeutics, Inc. Cost of Revenue History
FY2013-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$6.2M
FY2022
5-year range
$3.9M / $6.2M
FY2018-FY2022
Trend
+44.8%
vs FY2021
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cost of Revenue has increased for 3 consecutive years, from $4M in FY2019 to $6M in FY2022.
Based on SEC 10-K filings.
$6M in FY2022 with a 5-year CAGR of +6.8%.
Increased from $4M to $6M over the past 2 years.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- +16.4%
- 5-Year CAGR
- +6.8%
- 10-Year CAGR
- -
Key checks
Key Insights
- Perspective Therapeutics, Inc.'s cost of revenue has grown for 3 consecutive years.
- 5-year CAGR of +6.8%, indicating consistent growth.
- In FY2022, cost of revenue increased 44.8% year-over-year.
- Lowest cost of revenue in the period was in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 5.43 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2022 | $6.2M | +44.8% |
| FY2021 | $4.3M | +4.6% |
| FY2020 | $4.1M | +4.0% |
| FY2019 | $3.9M | -15.5% |
| FY2018 | $4.6M | +4.5% |
| FY2017 | $4.4M | +0.5% |
| FY2016 | $4.4M | +0.9% |
| FY2015 | $4.4M | +0.0% |
| FY2014 | $4.4M | +0.2% |
| FY2013 | $4.4M | - |
As of FY2022 · SEC 10-K · Updated Jun 24, 2026